In T2DM patients with (acute myocardial infarction) AMI, the use of SGLT2 inhibitors was associated with a lower risk of adverse cardiovascular outcomes during index hospitalization and long-term follow-up[42]. The gene discussed is SLC5A2; the disease is myocardial infarction.